← Leaderboards
James D Blanchard
Aradigm Corporation
$578,914
Attributed
$1,250,417
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $486.6K · FY2013–18$500K$375K$250K$125K$0
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$1,250,417 · 2
By mechanism
R44$972,649 · 1
R43$277,768 · 1
Top collaborators
- Luiz E Bermudez3 shared
- Igor Gonda1 shared
Others in their field
Top investigators on “Aerosolized”
- Kimberly A Prather · University Of California-Riverside$46,542,272
- Thomas Gary Ksiazek · University Of Texas Med Br Galveston$32,195,929
- Jeffery Dill · Battelle Centers/Pub Hlth Res & Evaluatn$30,023,104
- Barton F Haynes · Duke University$27,999,998
- Charles L Bailey · George Mason University$27,475,000
- Deepak Kaushal · University Of Chicago$26,419,545
Research focus
AerosolizedAids/Hiv ProblemAmikacinAnimalsAntibiotic ResistanceAntibioticsAntimycobacterial AgentsBacteriaBaseBenchmarkingBreathingBronchiectasisChronicChronic Lung DiseaseCiprofloxacinClarithromycinClinical EfficacyClinical ResearchClinical TrialsColony-Forming UnitsCombined AntibioticsCombined Modality TherapyCommercial ApplicationAdverse Effects
Grant awards (3)
In vitro and in vivo efficacy of liposomal ciprofloxacin formulations against Mycobacterium avium and Mycobacterium abscessus$486,050
R44 · FY2018 · AI · contact PI
In vitro and in vivo efficacy of liposomal ciprofloxacin formulations against Mycobacterium avium and Mycobacterium abscessus$486,599
R44 · FY2017 · AI · contact PI
In vitro and in vivo efficacy of liposomal ciprofloxacin formulations against Myc$277,768
R43 · FY2013 · AI · contact PI